The Michael J. Fox Foundation for Parkinson's Research has announced that it will commit up to $12 million in 2011 to support prioritized research toward transformative treatments and finding a cure for Parkinson's disease.
The funding will be awarded through MJFF's Pipeline Programs, which comprise the Therapeutics Development Initiative and the three Edmond J. Safra Core Programs for PD Research: the Rapid Response Innovation Awards, Target Validation, and the Clinical Intervention Awards. Through the programs, MJFF will support research focused on critical points along the translational pathway to new therapies for PD, including projects that test novel hypotheses, validate novel targets, catalyze and expand preclinical development, and clinically test novel therapies.
Later this year, additional research funds will be announced as part of MJFF's 2011 Critical Challenges initiatives, which provide funding for top MJFF research priorities and areas of particular emphasis.
"The Pipeline Programs are a core element of our foundation's efforts to drive research that will speed therapeutic development at historically underfunded points on the pipeline," said MJFF acting CEO Todd Sherer. "The programs are part of MJFF's progressive work to keep the most promising and significant projects moving forward toward notably improving quality of life for patients now and in the future."